Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma: reply from authors

Abstract

We thank the authors Lewis, Kim, and Duvic, for their reaction to our article.

The increasingly personalised medicine should also take into account individual tumour entities and their inter-individual pathways.

Therefore, we can only welcome and sustain the comments. As described in our article, it is possible, in some patients, to reduce the dose and interval frequency of Brentuximab Vedotin (BV), while continuing to have good efficacy.

This article is protected by copyright. All rights reserved.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2wimnoF